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A BST R AC T   
 
Aim: To evaluate the effect of vitamin D replacement on carpal tunnel syndrome (CTS) symptoms and signs 
in CTS patients with low vitamin D levels. 
Methods: This study was designed prospective observably. The patient population was admitted to the EMG 
(electromyography) laboratory in a tertiary hospital’s Physical Medicine and Rehabilitation Department 
between 1 January and 31 July 2018.  Initially, 55 patients were included in the study. The patients were 
categorized into two groups as group 1 (<10 ng / ml) and group 2 (10-20 ng / ml) according to the vitamin D 
levels. A total of 39 patients and 63 wrists, 17 patients in group 1 (28 wrists) and 22 patients in group 2 (35 
wrists), were included in the analysis. 
Results: There was a statistically significant decrease in visual analogue scale and quick arm-shoulder-hand 
disability score in two groups when compared before treatment. In two groups, there was a significant 
improvement in grip and pinch strength after treatment.  At the same time, after treatment we showed that 
there was a statistically significant increase in median nerve sensory amplitude in two groups. The increase in 
median nerve sensory velocity was significant in group 2 whereas it was not statistically significant between 
group 1 vs group 2.  
Conclusions: Vitamin D replacement can improve symptoms, functional status and electrophysiological 
findings in CTS patients with low vitamin D levels. 
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Introduction 
Carpal tunnel syndrome (CTS) is characterized 
by chronic compression of the median nerve 
through the carpal tunnel at the wrist. Most of 
the causes are idiopathic but diabetes mellitus 
(DM), thyroid disease, gout and pregnancy are 
known as the risk factors [1].  
Conservative treatment options for CTS include 
avoiding repetitive hand activities; splinting; 
local corticosteroid injections, oral 
corticosteroid treatment; physical therapy 
modalities; nerve gliding exercises [2]. Carpal 
tunnel release surgery is recommended for 
patients with severe CTS whose symptoms 
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have not improved with conservative treatment 
[3].  
Vitamin D (Vit D) is a steroid-like compound 
that can have hormone-like effects. Despite 
being known as a vitamin, it is distinguished 
from other vitamins as it can be synthesized in 
the body. Serum 25 hydroxyvitamin D 
(25(OH)D) levels indicate the adequate Vit D 
levels[4].  
In recent years, the neuroprotective effects of 
Vit D have been emphasized in the literature. 
Although the mechanism of this 
neuroprotective effect has not been fully 
elucidated yet, Vit D has been shown to have an 
antioxidant effect and this effect may play a role 
in preventing neuronal necrosis, and increasing 
myelinization by reducing the release of free 
radicals and blocking calcium channels  [5]. 
Animal studies have reported that Vit D has 
protective effects on neurons and decreases 
neuronal toxicity and damage [6]. Low level of 
Vit D levels in CTS are reported in small 
number of studies however, studies in which 
evaluating whether CTS symptoms and signs 
improve after Vit D replacement is limited[1]. 
In this study it is aimed to evaluate the 
symptoms and signs of CTS after Vit D 
replacement in mild-to-moderate CTS patients 
with low Vit D levels. The study hypothesizes 
that both the clinical and electrophysiological 
findings in CTS cases with low Vit D levels will 
improve in the third month following the 
initiation of Vit D replacement therapy. 
 
Materials and methods 
This research was designed as a single-center 
prospective observational study. An informed 
consent form was signed by and obtained from 
all patients who volunteered to participate in the 
study. The study was approved by the Ethics 
Committee of Health Sciences University, 
Clinics of Physical Medicine and Rehabilitation 
with the decision number 5/1, date 08/03/2018, 
and research number 2018-030.  
Vitamin D level < 20 ng/mL was considered to 
be low vitamin D level.  Patients aged 18–65 
years with a VitD level of <20 ng/mL, who 
were admitted to the outpatient clinic with CTS 
symptoms and signs within the period from 
January 2018 to July 2018, were evaluated in 
terms of eligibility for the study.  
The diagnosis of CTS was clarified based on 
clinical and electrodiagnostic criteria published 
jointly by the American Association of 
Electrodiagnostic Medicine (AAEM), 
American Academy of Neurology (AAN), and 
American Academy of Physical Medicine and 
Rehabilitation (AAPMR) in 2002 [7].  
Patients, who met all clinical criteria and had 
electrophysiological findings supporting 
median neuropathy at the wrist, were accepted 
as definite CTS. Among patients, who received 
the definite CTS diagnosis and were evaluated 
to be mild-to-moderate CTS based on their 
electrophysiological findings, were included in 
the study. Both wrists were considered as 
separate patients.  
Inclusion criteria of the study were being 18–65 
years of age, and having mild-to-moderate CTS 
with a VitD level below 20 ng/mL.  
Patients who were <18 and >65 years old; 
patients with normal VitD levels;  severe or 
very severe CTS; comorbidities including DM, 
chronic renal failure, chronic liver disease, 
thyroid disease, rheumatoid arthritis, systemic 
lupus erythematosus, scleroderma, gout, 
polymyositis, dermatomyositis, 
polyneuropathy, cervical radiculopathy, 
brachial plexopathy, and thoracic outlet 
syndrome;  vitamin B12 or folic acid deficiency 
a history of trauma; and previous carpal tunnel 
surgery were excluded (Figure 1).  
The patients were divided into two groups 
according to their VitD level. In Group 1  
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patients with a VitD level of <10 ng/mL 
(Critical VitD deficiency) and in Group 2 
patients with a VitD level of 10–20 ng/mL 
(VitD deficiency) were included. Splinting is 
recommended for all patients and VitD 
replacement therapy were applied in both 
groups. Cholecalciferol (vitamin D3) were 
given orally at a loading dose of 50,000 
IU/week for eight weeks as VitD replacement 
therapy. Afterward, the maintenance dose was 
given as 3000–6000 IU/day.  
During the 3-month follow up period, patients 
did not receive any physical therapy or median 






























Laboratory examinations, including a screening 
analysis of 25(OH)D levels, were performed 
using venous blood specimens. All serum 
25(OH)D (ng/mL) concentrations were 
analyzed using electrochemiluminescence 
immunoassay (ECLIA) technique with 
LIAISON analyzer (DiaSorin, Stillwater, MN). 
 
Evaluation of peripheral neuropathy and pain 
At baseline sociodemographic characteristics 
(age, gender, weight, height, occupation, hand 
dominance, disease duration) of the patients 
were recorded. (Table 1). The quick disabilities 
                        
                                                                                          
                                                                                      Figure 1. Patient flow chart. 
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of the arm, shoulder, and hand questionnaire 
(QuickDASH) was used to assess symptom 
severity, pain, and functional capability in the 
hand, while the pain intensity was assessed by 
visual analog scale (VAS). Patients completed 
these questionnaires at the beginning of the 
study and in the third month following the 
initiation of replacement therapy. 
 
Visual analogue scale (VAS) 
Patients were asked to rate their severity of 
hand or wrist pain on a 10-cm-long straight line 
with numbers, ranging from 0 to 10. Before the 
application, it was explained that the value 0 
represented no pain and the value 10 
represented the most severe pain they had ever 
felt.  
 
Quick disabilities of the arm, shoulder, and 
hand questionnaire (QuickDASH) 
This self-reported questionnaire was developed 
by the American Academy of Orthopaedic 
Surgeons (AAOS) in 1994 based on the model 
developed by the World Health Organization 
(WHO). It measures physical function and 
symptoms of patients suffering from upper 
extremity problems. The questionnaire contains 
disability/symptom scale (11 items) and 2 
optional scales (work (4 items) and 
sports/performing arts (4 items)). Each question 
is scored between 1 and 5. Each subscales 
ranged between 0 (no disability) and 100 (most 
severe disability). The reliability and validity of 
the Turkish version of the questionnaire in 
patients with CTS was conducted by Koldaş 
Doğan Ş et al.[8] among patients with CTS. It 
is completed in about five to seven minutes, 
with moderate ease of scoring [9].  
 
Measurement of grip and pinch strength                                                         
Grip and pinch strengths were measured at the 
beginning of the study and at the third month of 
treatment. An electronic hand dynamometer 
[Electronic Hand Dynamometer (HS-005), 
China] was used to measure grip strength 
whereas finger grip strength was measured 
using a manual pinchmeter (Sammons Preston, 
Inc. Bolingbrook, IL 60440-4989). The results 
were recorded in kilograms (kg). Handgrip 
strength measurements were performed while 
the patient was in the sitting position, the arm 
was in adduction, the forearm was in 90° 
flexion and neutral position, and the wrist was 
in 0–30° extension and 0–15° ulnar abduction 
position. Patients were asked to give full 
maximum voluntary effort grip [10]. In the test 
procedure, a total of three measurements were 
made by taking a break between each 
measurement for grip and pinch strengths and 
their averages were recorded [11, 12]. 
 
Electrophysiological evaluation 
All electrophysiological evaluations were 
performed using Nihon Kohden Neuropack S1 
MEB-9400K EMG Device (Tokyo, Japan). All 
patients were evaluated electrophysiologically 
at the beginning of the treatment and at the third 
month of treatment. All nerve conduction 
studies were performed by the same physician 
using bipolar superficial electrodes, the same 
device, and standard technique, in accordance 
with the relevant guidelines. Median and ulnar 
sensory nerve conduction and distal (wrist) and 
proximal (elbow) motor nerve conduction were 
studied on the one hand, and median sensory 
nerve conduction and distal and proximal motor 
nerve conduction were studied on the other 
hand [13, 14]. 
 
Statistical analysis 
Statistical analysis was performed using SPSS 
version 20.0 software (IBM Corporation, 
Armonk, NY, USA). Using the G-Power 
analysis, the sample size was calculated by 
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taking the power as 90%, alpha value as 0.05,  
and effect value as 0.2. To the best of our 
knowledge, there were no studies evaluating 
Vit D replacement therapy in line with the 
purpose of this study. Therefore, studies 
comparing the VAS score and CTS severity of 
mild-to-moderate CTS patients with low and 
normal Vit D levels were utilized to calculate 
the effect value. The Shapiro–Wilk test was 
used to determine whether the groups followed 
































expressed as mean, standard deviation, median, 
highest and lowest values, frequency, and ratio. 
The means of variables following normal 
distribution were compared using Student's t-
test. In variables not following a normal 
distribution, the Wilcoxon signed-rank test was 
used for dependent groups whereas the Mann–
Whitney U test test was used for independent 
groups. Chi-Square and McNemar tests were 
used in categorical variables. A p value of 
































Tablo  1. Demographic status of the patients. 
 
Parameters  








Wrist  28 35  
Age (years) (mean±SD) 47.82±8,47 46.14±8,46 0.541
a 
Gender (n, %)  
      Female  
      Male 
17 (100) 20 (90.9) 
 
0.202b 
0 ( 0.0) 2 (9.1) 
Working status  (n, %)  
      Work  
      Not working  
      Retired 
5 (29.4) 7 (31.8) 
 
0.907b 
11 (64.7) 13 (59.1) 
1 (5.9) 2 (9.1) 
Length (cm) (mean±SD) 
158.59±6.12 159.18±6,58 
0.775 a 
Weight (kg) (mean±SD) 
72.12±12.22 70.59±14.23 
0.460 c 
BMI (kg/m2) (mean±SD) 
28.49±5.63 27.62±4.07 
0.580 a 
Symptom time (month) 
(mean±SD) 5.65±2.89 4.59±2.44 
0.177 c 
Dominant  hand (n, %)  
       Right  
       Left 
13 (76.5) 19 (86.4) 
 
0.425b 
4 (23.5) 3 (1.6) 
Symptomatic hand (n, %)  
       Right  
       Left  
       Bilaterally 
6 (35.3) 5 (22.7) 
 
0.159b 
0 (0.0) 4 (18.2) 
11 (64.7) 13 (59.1) 
a; Student T test was used.   Mean±Standart deviation (SD) was showen. b; Chi-square test was used.    
c; Mann-Whitney U was used.   Mean±Standart deviation (SD) was showen. 
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At the initial phase of the study, a total of 55 
patients meeting the inclusion criteria were 
included. Nine patients were excluded due to 
the presence of exclusion criteria and seven 
patients were excluded from the study because 
they did not come for post-treatment controls.  
A total of 63 wrists were included in the 
analyses. All of these patients were given Vit D 
replacement. The patient flow chart is shown in 
Figure 1. The mean age of the patients was 
46.87±8.39 years. The symptom duration of the 
patients was 5.65±2.89 and 4.59±2.44 months 
in Group 1 and Group 2, respectively. 
Demographic characteristics of the patients 
were given in Table 1 
In both groups, Vit D levels were observed to 
be statistically significantly increased in 
posttreatment compared to baseline (p=0.000 
and p=0000 for Group 1 and Group 2, 
respectively). Similarly, there were statistically 
significant decreases in VAS scores in both 
groups after treatment (VAS day/night 
p=0.021, p=0.012, p=0.000, and p=0.000 for 


















groups, statistically significant decreases were 
found in the QuickDASH symptom and job 
subscores measured after treatment compared 
to pre-treatment (p=0.000 and p=0.002; 
p=0.000 and p=0.000 for Group 1 and Group 
2, respectively). There were also statistically 
significant differences between groups in terms 
of grip and pinch strengths after treatment 
compared to pre-treatment (p=0.026 and 
p=0.030). At Post-treatment grip strengths of 
both groups were increased compared to pre-
treatment values (p=0.003 and p=0.000 for 
Group 1 and Group 2, respectively). There was 
no statistically significant difference in the 
pinch strengths (p=0.892 and p=0.079 for 
Group 1 and Group 2, respectively) between the 
groups. The rate of patients whose VitD levels 
returned to normal after treatment was 10.7% in 
Group 1 and 22.7% in Group 2. This 
improvement rate was found to be statistically 
significant (p=0.012 and p=0.039 for Group 1 
and Group 2, respectively). The pre and 
posttreatment values of the pain severity and 
functional status of the patients were given in 


















Table 2. Comparison between the patients of functional and pain scores before and after vitamin D replacement. 
Parameters  
Group 1 
Critical Vit D deficiency 
(n=17) 
Group 2 
Vit D deficiency 
(n=22) 
P1 P2 P3 P4 
Variable 



















Group 2 for 
BT 
Group 1 





7.29±1.96 19.52±4.72 17.09±3.11 25.62±5.35 0.000 b 0.000 b 0.000a 0.001 a 
Quick Dash  Score 55.86±9.12 48.77±8.95 51.55±8.93 44.70±10.41 0.000 b 0.002 b 0.148a 0.207 a 
Quick Dash work 
model 
46.69±11.92 42.77±9.80 43.58±12.50 36.65±12.98 0.000 b 0.000 b 0.438a 0.114 a 
Grip strengths 
(kg) 
20.36±5.72 22.50±4.76 22.86±5.58 25.63±5.84 0.003b 0.000b 0.086a 0.026a 
Pinch strengths 
(kg) 
5.48±1.52 5.43±1.50 5.71±1.99 6.26±1.45 0.892b 0.079 b 0.613a 0.030a 
VAS (morning) 2.88±0.99 2.35±0.77 2.95±1.09 1.91±1.31 0.021d 0.000 d 0.906c 0.930c 
VAS (Night) 5.35±1.06 4.59±0.80 5.41±1.14 4.05±1.53 0.012 d 0.000 d 0.342c 0.325c 
Mild CTS 
(n, %) 
12(42.9) 3 (10.7) 16(45.7) 8 (22.7) 
0.012e 0.039e 0.821e 0.354e 
Moderate CTS 
(n, %) 
16(57.1) 7 (25.0) 19(54.3) 10 (28.6) 
İmproved CTS 
(n, %) 
 18 (64.3)  17 (48.6) 
a; Student T test was used.   b;T test was used at  the dependet groups.  c;Mann-Whitney U was used.  d;Wilcoxon Test was used.          
e: Chi-square and Mc Nemar test test was used. CTS: Carpal Tunnel Syndrome    Mean±Standart deviation (SD) was showen. 
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There was no statistically significant difference 
between the two groups in terms of pre-
treatment and post-treatment 
electrophysiological findings. Only median 
nerve sensory amplitude (SA) and sensory 
conduction velocity (SCV) were increased in 
both groups. A statistically significant increase 
was found in the median nerve SA after 
treatment compared to before treatment in both 
groups (p=0.043 and p=0.017 for Group 1 and 
Group 2, respectively). The increase in median 
nerve SCV was significant in Group 2 whereas 
it was not statistically significant in Group 1 
(p=0.168 and p=0.036 for Group 1 and Group 
2, respectively). Table 3 shows the changes in 




Several studies have shown that patients with 
CTS have lower Vit D levels. While Vit D 
deficiency has been reported to increase the 
severity of pain in CTS cases in a study, low Vit 
D levels have been suggested to trigger CTS 


















In a study by Nageeb et al. [18] involving 50 
patients with CTS and 50 healthy individuals, 
in which the effects of Vit D level on CTS was 
investigated, the authors compared the Vit D 
levels of patients with severe CTS and patients 
with mild-to-moderate CTS and found that Vit 
D levels were significantly lower in those with 
severe CTS. There are studies indicating that 
Vit D has  protective effects on neurons and 
decreases neuronal toxicity and damage by 
suppressing the cytokine pathway [19]. In a 
study by Shebab et al. [20] in 2015 
investigating the effects of Vit D on peripheral 
neuropathy, 112 patients with type II DM 
accompanied by peripheral neuropathy were 
given 50,000 IU cholecalciferol once a week for 
eight weeks and the authors reported a 
significant increase in Vit D levels and a 
significant improvement in neuropathy 
symptom scores in the treatment group 
compared to the placebo group at the end of 
eight weeks.  
In a recent study by Sacmaci et al. [21], Vit D 
values of patients with moderate CTS were 


















Table 3: Comparison between the patients of the electrophsical evaluations before and after vitamin D replacement. 
Parameters 
Group 1 























BT vs AT 
Group 1vs 
Group 2 for 
BT 
Group 1 




4.03±0.80 4.17±0.72 37.72±4.49 39.14±6.02 0.061c 0.277c 0.857b 0.323b 
Median nerve 
MA (m/s) 




60.24±6.15 57.50±6.08 58.63±6.51 57.77±5.07 0.750d 0.373d 0.175a 0.605a 
Median Nerve 
DSOL (ms) 
3.20±0.42 3.24±0.47 3.27±0.47 3.30±0.51 0.707c 0.353c 0.538b 0.771b 
Median Nerve 
SA(mV) 
17.16±6.88 18.30±6.59 18.44±8.96 19.34±8.91 0.043d 0.017d 0.643b 0.606 
Median Nerve 
SCV (m/s) 
38.18±3.89 39.03±3.78 3.96±0.70 4.03±0.75 0.168c 0.036c 0.841b 0.934b 
a; Student T test was used.  b; Mann-Whitney U was used. c; Wilcoxon Test was used. d; T test was used at  the dependet groups.        Mean ±Standart 
deviation (SD) was showen. DSOL: Distal Sensory Onset Latency. DML: Distal motor latency.  MCV: Motor Conduction velocity. SCV:  Sensory 
Conduction Velocity    SA: sensory amplitude. MA: motor Amplitude. 
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month after replacement therapy compared to 
pre-treatment. Similar to this study, we found a 
statistically significant increase in post-
treatment Vit D levels of both groups. Akyuz et 
al. [22] reported a significant improvement in 
pain and quality of life after eight-weeks of Vit 
D treatment in patients with chronic widespread 
pain; however, they further examined the 
patients electrophysiologically and did not 
identify any significant changes in nerve 
conduction studies following the Vit D 
supplementation. In a study by Sacmaci et al. 
[21] involving 50 female patients (45 wrists 
with mild CTS and 37 wrists with moderate 
CTS), an improvement was observed in both 
groups after treatment compared to pre-
treatment. Consistent with these findings, in the 
present study, a statistically significant 
improvement was observed in both day and 
night VAS scores of both groups after the 
treatment.  
Measuring the grip strength in CTS cases is 
important for the evaluation of the patients. 
Gumieiro et al. [23] showed that individuals 
suffering from Vit D insufficiency had 
insufficient grip strength. In the present study, 
the grip strength of patients in both groups was 
increased after treatment and increase in Group 
2 is significantly greater than in Group 1 which 
can be interpreted as less muscle strength loss 
since patients in Group 2 have higher Vit D 
levels. Post-treatment pinch strength was 
observed to decrease in Group 1, whereas it 
increased in Group 2; however, this increase in 
Group 2 was not statistically significant. While 
the pre-treatment QuickDASH scores were 
similar in both groups, there were statistically 
significant decreases after treatment in both 
groups, and there was no significant difference 
between the groups.  
In a study investigating the effect of Vit D on 
peripheral neuropathy, the authors divided 
patients with DM accompanied by 
polyneuropathy into treatment and placebo 
groups and evaluated them 
electrophysiologically after eight weeks of Vit 
D treatment. The treatment group was observed 
to have lower values in median nerve motor and 
sensory distal latencies, higher values in 
median nerve SCV and median nerve motor and 
SAs, and lower values in the median nerve 
motor conduction velocity (MCV) compared to 
the placebo group. None of these differences 
were found to be statistically significant [20].In 
a study examining Vit D levels of CTS patients, 
Vit D levels were found to have a positive 
correlation with MCV and a negative 
correlation with distal motor latency (DML). In 
the same study, CTS patients were classified as 
mild, moderate, and severe, and patients with 
severe CTS were observed to have the lowest 
Vit D levels [18]. A similar study was 
conducted by Tanik et al. [24], in which the 
authors found a positive correlation between 
the severity of Vit D deficiency and the severity 
of CTS. In a study by Sacmaci et al. [21], 
involving 50 female patients (45 wrists with 
mild CTS and 37 wrists with moderate CTS), 
an improvement in nerve conduction values 
was reported in both groups. Shortening in 
median nerve distal sensory onset latency 
(DSOL) and an increase in SCV were found to 
be statistically significant in the mild CTS 
group. In the moderate CTS group, an increase 
in SA and SCV and a shortening in DML were 
found to be significant. In the present study, an 
increase was found only in the median nerve SA 
and SCV in both groups. A statistically 
significant increase was found in the post-
treatment median nerve SA in both groups. It 
was observed that SCV showed a statistically 
significant increase only in Group 2. The 
positive effect of Vit D on both myelinization 
and axonogenesis, which has been shown in 
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animal studies, is compatible with the results 
presented here [6, 25]. However, we attribute 
the presence of a more significant increase in 
SCV only in Group 2 to the fact that the patients 
in this group have higher Vit D levels. In Group 
1 with lower Vit D levels, mild and moderate 
CTS rates were 42.9% and 57.1%, respectively, 
whereas these rates were found to be 45.7% and 
54.3% in Group 2, respectively. This difference 
between the two groups was not statistically 
significant. Post-treatment findings were found 
to be normal in 10.7% of Group 1 and 22.7% of 
Group 2. Similarly, the reason for the higher 
rate of normal findings in Group 2 may be that 
the patients in this group have higher Vit D 
levels.   
One of the important limitations of this study is 
that as required by routine treatment, all 
patients were given hand-wrist splint in 
addition to Vit D replacement therapy. The 
absence of a control group that obtained either 
a hand-wrist splint or a placebo group makes 
evaluating the efficacy of Vit D difficult. 
Furthermore, the inclusion of a small number of 
patients and a short follow-up period are other 
limitations. There is a need for studies with 
longer follow-up periods, particularly for 
electrophysiological evaluations. 
Conclusions 
In CTS patients with low Vit D levels, Vit D 
replacement therapy can reduce symptoms and 
improve functional status, as well as 
electrophysiological findings. When the 
subgroups are evaluated according to the 
severity of Vit D deficiency, those with higher 
Vit D levels show more improvement in terms 
of pain, functional status, and 
electrophysiological findings. Prospective 
randomized-controlled trials with longer 
treatment and follow-up periods, in which the 
efficacy of Vit D in CTS patients is evaluated 
are needed. 
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